Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328043 | 0.71 | SLC9A1 (0.55) | SLC9A1KEAP1HCAR3RAB9AHPGD | |
| SCHEMBL31257708 | 0.69 | HCAR3 (0.45) | SLC9A1KEAP1HCAR3RAB9AHPGD | |
| SCHEMBL18322072 | 0.69 | KEAP1 (0.42) | SLC9A1KEAP1HCAR3RAB9AHPGD | |
| SCHEMBL31257572 | 0.69 | KEAP1 (0.42) | SLC9A1KEAP1HCAR3RAB9AHPGD | |
| SCHEMBL435034 | 0.67 | HCAR3 (0.56) | SLC9A1KEAP1HCAR3RAB9AHPGD | |
| SCHEMBL12775742 | 0.67 | SLC9A1 (0.50) | SLC9A1KEAP1HCAR3RAB9AHPGD | |
| SCHEMBL3673451 | 0.65 | SLC9A1 (0.95) | SLC9A1KEAP1HCAR3RAB9APOLB | |
| Ammonia Solution, Strong SCHEMBL4635177 | 0.65 | SLC9A1 (0.95) | SLC9A1KEAP1HCAR3RAB9APOLB | |
| SCHEMBL2925766 | 0.65 | SLC9A1 (0.95) | SLC9A1KEAP1HCAR3RAB9APOLB | |
| SCHEMBL31257518 | 0.65 | HCAR3 (0.41) | SLC9A1KEAP1HCAR3RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018198-B2 | Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | UNIVERSITY OF MARYLAND (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140274983-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274983-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP21A2, HSD17B11, CYP19A1 | SLC9A1 2486/4885KEAP1 2768/4885HCAR3 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.